Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Shi, T., McAllister, D., O’Brien, K. L., Simões, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acácio, S., Aguayo, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30938-8 · Cited by 2,382 · see citing works

Correlates of protection induced by vaccination

Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745 · see citing works

Immunological mechanisms of vaccination

Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,085 · see citing works

AN EPIDEMIOLOGIC STUDY OF ALTERED CLINICAL REACTIVITY TO RESPIRATORY SYNCYTIAL (RS) VIRUS INFECTION IN CHILDREN PREVIOUSLY VACCINATED WITH AN INACTIVATED RS VIRUS VACCINE

Kapikian, A. Z., MITCHELL, R. H., Chanock, R. M., Shvedoff, R. A., & STEWART, C. E. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120954 · Cited by 1,035 · see citing works

Vaccines: Correlates of Vaccine‐Induced Immunity

Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829 · see citing works

Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

Groothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292102 · Cited by 744 · see citing works

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

Glezen, W. P., Paredes, A., Allison, J. E., Taber, L. H., & Frank, A. L. (1981) · The Journal of Pediatrics · doi:10.1016/s0022-3476(81)80829-3 · Cited by 684 · see citing works

Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants

Blanken, M. O., Rovers, M. M., Molenaar, J. M., Winkler-Seinstra, P., Meijer, A., Kimpen, J. L. L., & Bont, L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211917 · Cited by 670 · see citing works

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

Johnson, S., Oliver, C. N., Prince, G. A., Hemming, V. G., Pfarr, D. S., Wang, S., Dormitzer, M., O'Grady, J., Koenig, S., Tamura, J. K., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514115 · Cited by 642 · see citing works

FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION1

CHIN, J., Magoffin, R. L., Shearer, L. A., SCHIEBLE, J. H., & Lennette, E. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120957 · Cited by 630 · see citing works

RESPIRATORY VIRUS IMMUNIZATION

Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W., Minamitani, M., & Meiklejohn, G. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120956 · Cited by 609 · see citing works

Antibody validation

Bordeaux, J., Welsh, A. W., Agarwal, S., Killiam, E. J., Baquero, M. T., Hanna, J. A., Anagnostou, V., & Rimm, D. L. (2010) · BioTechniques · doi:10.2144/000113382 · Cited by 597 · see citing works

The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection

Welliver, R. C., Wong, D. T., Sun, M., Middleton, E., Vaughan, R. S., & Ogra, P. L. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110083051501 · Cited by 529 · see citing works

Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)

Mallery, D. L., McEwan, W. A., Bidgood, S. R., Towers, G. J., Johnson, C. M., & James, L. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014074107 · Cited by 517 · see citing works

Taxonomy of the order Mononegavirales: update 2016

Afonso, C. L., Amarasinghe, G. K., Bànyai, K., Bào, Y., Basler, C. F., Bavari, S., Bejerman, N., Blasdell, K. R., Briand, F., Briese, T., et al. (2016) · Archives of Virology · doi:10.1007/s00705-016-2880-1 · Cited by 493 · see citing works

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

Miller, E. J., SALISBURY, D. M., & Ramsay, M. E. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 483 · see citing works

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

Tripp, R. A., Jones, L. P., Haynes, L. M., Zheng, H., Murphy, P. M., & Anderson, L. J. (2001) · Nature Immunology · doi:10.1038/90675 · Cited by 457 · see citing works

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

McLellan, J. S., Yang, Y., Graham, B. S., & Kwong, P. D. (2011) · Journal of Virology · doi:10.1128/jvi.00555-11 · Cited by 433 · see citing works

Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

Ngwuta, J. O., Chen, M., Modjarrad, K., Joyce, M. G., Kanekiyo, M., Kumar, A., Yassine, H. M., Moin, S. M., Killikelly, A. M., Chuang, G., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4241 · Cited by 433 · see citing works

Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group

Maslanka, S., Gheesling, L. L., Libutti, D. E., Donaldson, K. B. J., Harakeh, H. S., Dykes, J. K., Arhin, F. F., Devi, S. J., Frasch, C. E., Huang, J., et al. (1997) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.4.2.156-167.1997 · Cited by 427 · see citing works

HUMAN IMMUNITY TO THE MENINGOCOCCUS

Gotschlich, E. C., Goldschneider, I., & Artenstein, M. S. (1969) · The Journal of Experimental Medicine · doi:10.1084/jem.129.6.1367 · Cited by 402 · see citing works

Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21

McEwan, W. A., Tam, J. C. H., Watkinson, R. E., Bidgood, S. R., Mallery, D. L., & James, L. C. (2013) · Nature Immunology · doi:10.1038/ni.2548 · Cited by 374 · see citing works

MicroRNA-29 Regulates T-Box Transcription Factors and Interferon-γ Production in Helper T Cells

Steiner, D. F., Thomas, M. F., Hu, J. K., Yang, Z., Babiarz, J., Allen, C. D. C., Matloubian, M., Blelloch, R. H., & Ansel, K. M. (2011) · Immunity · doi:10.1016/j.immuni.2011.07.009 · Cited by 365 · see citing works

Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern

Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R., & Anderson, L. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.2852-2860.1996 · Cited by 363 · see citing works

Broadly Neutralizing Antibodies Elicited by the Hypervariable Neutralizing Determinant of HIV-1

Javaherian, K., Langlois, A. J., LaRosa, G. J., Profy, A. T., Bolognesi, D. P., Herlihy, W. C., Putney, S. D., & Matthews, T. J. (1990) · Science · doi:10.1126/science.1703322 · Cited by 353 · see citing works

Nomenclature for Immune Correlates of Protection After Vaccination

Plotkin, S. A., & Gilbert, P. B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis238 · Cited by 348 · see citing works

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10

Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C.-Y., Morse, H. C., & Murphy, B. R. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.5321-5325.1994 · Cited by 347 · see citing works

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

Ramsay, M. E., Andrews, N. J., Kaczmarski, E. B., & Miller, E. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03594-7 · Cited by 337 · see citing works

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

BLACK, S. B., Nicolay, U., Vesikari, T., Knuf, M., Giudice, G. D., Cioppa, G. D., Tsai, T. F., Clemens, R. L., & Rappuoli, R. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182367662 · Cited by 333 · see citing works

Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England

Andrews, N. J., Borrow, R., & Miller, E. J. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.5.780-786.2003 · Cited by 323 · see citing works

Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection

Borrow, R., Andrews, N. J., Goldblatt, D., & Miller, E. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1568-1573.2001 · Cited by 317 · see citing works

Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing

Simões, E. A. F., Groothuis, J. R., Carbonell‐Estrany, X., Rieger, C., Mitchell, I., Fredrick, L. M., & Kimpen, J. L. L. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.02.032 · Cited by 304 · see citing works

Host Cell Entry of Respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F Protein

Krzyzaniak, M. A., Zumstein, M., Gerez, J., Picotti, P., & Helenius, A. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003309 · Cited by 281 · see citing works

Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion

Russell, C. J., Jardetzky, T. S., & Lamb, R. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4024 · Cited by 280 · see citing works

Estimation of Vaccine Effectiveness Using the Screening Method

Farrington, P. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.4.742 · Cited by 261 · see citing works

Surrogate Endpoints And FDA’s Accelerated Approval Process

Fleming, T. R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.1.67 · Cited by 252 · see citing works

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

Prince, G. A., Horswood, R. L., & Chanock, R. M. (1985) · Journal of Virology · doi:10.1128/jvi.55.3.517-520.1985 · Cited by 245 · see citing works

Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion

González-Reyes, L., Ruiz-Argüello, M. B., García‐Barreno, B., Calder, L. J., López, J. A., Albar, J. P., Skehel, J. J., Wiley, D. C., & Melero, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151098198 · Cited by 242 · see citing works

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

Piedra, P. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00355-4 · Cited by 229 · see citing works

Maternal antibody and respiratory syncytial virus infection in infancy

OGILVIE, M. M., Vathenen, A. S., Radford, M., Codd, J. D., & Key, S. (1981) · Journal of Medical Virology · doi:10.1002/jmv.1890070403 · Cited by 226 · see citing works

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

Simões, E. A. F., Carbonell‐Estrany, X., Rieger, C., Mitchell, I., Fredrick, L. M., & Groothuis, J. R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.026 · Cited by 222 · see citing works

Taxonomy of the order Mononegavirales: update 2017

Amarasinghe, G. K., Bào, Y., Basler, C. F., Bavari, S., Beer, M., Bejerman, N., Blasdell, K. R., Bochnowski, A., Briese, T., Bukreyev, A. A., et al. (2017) · Archives of Virology · doi:10.1007/s00705-017-3311-7 · Cited by 220 · see citing works

Correlates of protection to influenza virus, where do we go from here?

Cox, R. J. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22908 · Cited by 209 · see citing works

A Framework for Assessing Immunological Correlates of Protection in Vaccine Trials

Li, Q., Gilbert, P. B., Corey, L., McElrath, M. J., & Self, S. G. (2007) · The Journal of Infectious Diseases · doi:10.1086/522428 · Cited by 205 · see citing works

HUMAN IMMUNITY TO THE MENINGOCOCCUS

Gotschlich, E. C., Goldschneider, I., & Artenstein, M. S. (1969) · The Journal of Experimental Medicine · doi:10.1084/jem.129.6.1385 · Cited by 199 · see citing works

A Guide to the Perplexed on the Specificity of Antibodies

Saper, C. B. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.952770 · Cited by 185 · see citing works

Structural basis of respiratory syncytial virus neutralization by motavizumab

McLellan, J. S., Chen, M., Kim, A., Yang, Y., Graham, B. S., & Kwong, P. D. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1723 · Cited by 182 · see citing works

Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study

Mochizuki, H., Kusuda, S., Okada, K., Yoshihara, S., Furuya, H., & Simões, E. A. F. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1812oc · Cited by 172 · see citing works

Accessibility Control of V(D)J Recombination

Cobb, R. M., Oestreich, K. J., Osipovich, O. A., & Oltz, E. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)91002-5 · Cited by 161 · see citing works

Role of Maternal Antibody in Pneumonia and Bronchiolitis Due to Respiratory Syncytial Vims

Lamprecht, C. L., Krause, H. E., & Mufson, M. A. (1976) · The Journal of Infectious Diseases · doi:10.1093/infdis/134.3.211 · Cited by 160 · see citing works

A brief history of the global effort to develop a preventive HIV vaccine

Esparza, J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.018 · Cited by 155 · see citing works

Pneumococcal vaccine and opsonic pneumococcal antibody

Song, J. Y., Moseley, M. A., Burton, R. L., & Nahm, M. H. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0601-1 · Cited by 155 · see citing works

Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus

Killikelly, A. M., Kanekiyo, M., & Graham, B. S. (2016) · Scientific Reports · doi:10.1038/srep34108 · Cited by 151 · see citing works

Immunopathology in RSV Infection Is Mediated by a Discrete Oligoclonal Subset of Antigen-Specific CD4+ T Cells

Varga, S. M., Wang, X., Welsh, R. M., & Braciale, T. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00209-6 · Cited by 147 · see citing works

Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants

Yoshihara, S., Kusuda, S., Mochizuki, H., Okada, K., Nishima, S., & Simões, E. A. F. (2013) · PEDIATRICS · doi:10.1542/peds.2013-0982 · Cited by 146 · see citing works

Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats

Prince, G. A., Hemming, V. G., Horswood, R. L., Baron, P. A., & Chanock, R. M. (1987) · Journal of Virology · doi:10.1128/jvi.61.6.1851-1854.1987 · Cited by 146 · see citing works

Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses

Harcourt, J. L., Alvarez, R., Jones, L. P., Henderson, C. A., Anderson, L. J., & Tripp, R. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1600 · Cited by 143 · see citing works

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

Sáez‐Llorens, X., Castaño, E., Null, D. M., Steichen, J. J., Sánchez, P. J., Ramilo, O., Top, F. H., & Connor, E. M. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199809000-00007 · Cited by 136 · see citing works

Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice

Haynes, L. M., Caidi, H., Radu, G. U., Miao, C., Harcourt, J. L., Tripp, R. A., & Anderson, L. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/600108 · Cited by 133 · see citing works

Quest for Correlates of Protection against Tuberculosis

Bhatt, K., Verma, S., Ellner, J. J., & Salgame, P. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00721-14 · Cited by 129 · see citing works

Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze

Stensballe, L. G., Ravn, H., Kristensen, K., Agerskov, K., Meakins, T., Aaby, P., & Simões, E. A. F. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.10.043 · Cited by 126 · see citing works

Antibodies to Respiratory Syncytial Virus Polypeptides and their Significance in Human Infection

Ward, K. A., Lambden, P. R., OGILVIE, M. M., & Watt, P. J. (1983) · Journal of General Virology · doi:10.1099/0022-1317-64-9-1867 · Cited by 125 · see citing works

Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.

Profy, A. T., Salinas, P. A., Eckler, L., Dunlop, N. M., Nara, P. L., & Putney, S. D. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.12.4641 · Cited by 124 · see citing works

Eosinophilia at the Time of Respiratory Syncytial Virus Bronchiolitis Predicts Childhood Reactive Airway Disease

Ehlenfield, D. R., Cameron, K. A., & Welliver, C. (2000) · PEDIATRICS · doi:10.1542/peds.105.1.79 · Cited by 122 · see citing works

Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Gold, R., & Artenstein, M. S. (1971) · Europe PMC (PubMed Central) · Cited by 121 · see citing works

Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.

Groothuis, J. R., Simões, E. A. F., & Hemming, V. G. (1995) · PubMed · Cited by 120 · see citing works

Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven Immunopathology

Walzl, G., Matthews, S. P., Kendall, S. L., Gutierrez‐Ramos, J. C., Coyle, A. J., Openshaw, P., & Hussell, T. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.785 · Cited by 119 · see citing works

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine

Ambrose, C. S., Wu, X., Jones, T., & Mallory, R. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.018 · Cited by 115 · see citing works

Complex immune correlates of protection in HIV ‐1 vaccine efficacy trials

Tomaras, G. D., & Plotkin, S. A. (2017) · Immunological Reviews · doi:10.1111/imr.12514 · Cited by 110 · see citing works

Seasonal Variation of Maternally Derived Respiratory Syncytial Virus Antibodies and Association with Infant Hospitalizations for Respiratory Syncytial Virus

Stensballe, L. G., Ravn, H., Kristensen, K., Meakins, T., Aaby, P., & Simões, E. A. F. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.07.053 · Cited by 106 · see citing works

On the nature of crossreactions observed with antibodies directed to defined epitopes.

Nigg, E. A., Walter, G., & Singer, S. J. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.19.5939 · Cited by 105 · see citing works

Respiratory viruses and eosinophils: Exploring the connections

Rosenberg, H. F., Dyer, K. D., & Domachowske, J. B. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.04.005 · Cited by 104 · see citing works

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

Huang, K., Incognito, L., Cheng, X., Ulbrandt, N. D., & Wu, H. (2010) · Journal of Virology · doi:10.1128/jvi.02699-09 · Cited by 101 · see citing works

Specificity Controls for Immunocytochemistry

Holmseth, S., Zhou, Y., Follin-Arbelet, V. V., Lehre, K. P., Bergles, D. E., & Danbolt, N. C. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411434828 · Cited by 95 · see citing works

Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice

Zhang, W., Choi, Y., Haynes, L. M., Harcourt, J. L., Anderson, L. J., Jones, L. P., & Tripp, R. A. (2009) · Journal of Virology · doi:10.1128/jvi.01755-09 · Cited by 93 · see citing works

The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches

Haralambieva, I. H., Ovsyannikova, I. G., Pankratz, V. S., Kennedy, R. B., Jacobson, R. M., & Poland, G. A. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.134 · Cited by 92 · see citing works

Is interferon-gamma the right marker for bacille Calmette–Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology

Abebe, F. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04614.x · Cited by 90 · see citing works

Immunoglobulin (IgG) and (IgM) Antibody Responses to Rabies Vaccine

Turner, G. S. (1978) · Journal of General Virology · doi:10.1099/0022-1317-40-3-595 · Cited by 80 · see citing works

Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells

Bidgood, S. R., Tam, J. C. H., McEwan, W. A., Mallery, D. L., & James, L. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410980111 · Cited by 78 · see citing works

Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins

Fuentes, S., Coyle, E. M., Beeler, J. A., Golding, H., & Khurana, S. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005554 · Cited by 77 · see citing works

Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development

Melero, J. A., Más, V., & McLellan, J. S. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.09.045 · Cited by 73 · see citing works

Global practices of meningococcal vaccine use and impact on invasive disease

Ali, A., Jafri, R. Z., Messonnier, N. E., Tévi‐Bénissan, C., Dürrheim, D. N., Eskola, J., Fermon, F., Klugman, K. P., Ramsay, M. E., Sow, S. O., et al. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000126 · Cited by 72 · see citing works

Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant

Schneider-Ohrum, K., Cayatte, C., Bennett, A. S., Rajani, G. M., McTamney, P. M., Nacel, K., Hostetler, L., Cheng, L., Ren, K., O’Day, T. L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02180-16 · Cited by 72 · see citing works

Mechanisms of antigen receptor evolution

Eason, D. D., Cannon, J. P., Haire, R. N., Rast, J. P., Ostrov, D. A., & Litman, G. W. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2004.08.001 · Cited by 70 · see citing works

Experimental rabies vaccines for humans

McGettigan, J. P. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.105 · Cited by 69 · see citing works

New insights for development of a safe and protective RSV vaccine

Blanco, J. C. G., Boukhvalova, M. S., Shirey, K. A., Prince, G. A., & Vogel, S. N. (2010) · Human Vaccines · doi:10.4161/hv.6.6.11562 · Cited by 69 · see citing works

Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naive and Formalin-Inactivated RSV-Immunized BALB/c Mice

Radu, G. U., Caidi, H., Miao, C., Tripp, R. A., Anderson, L. J., & Haynes, L. M. (2010) · Journal of Virology · doi:10.1128/jvi.00451-10 · Cited by 68 · see citing works

Respiratory syncytial virus-specific immunoglobulins in preterm infants

de Sierra, T. M., KUMAR, M. L., Wasser, T., Murphy, B. R., & Subbarao, K. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(06)80027-2 · Cited by 67 · see citing works

Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus

Luchsinger, V., Piedra, P. A., Ruiz, M., Zunino, E., Martínez, M., Machado, C. M., Fasce, R., Ulloa, M. T., Fink, M. C. D., Lara, P., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir955 · Cited by 66 · see citing works

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

Pace, D., & Pollard, A. J. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.111500 · Cited by 65 · see citing works

Progress toward a Respiratory Syncytial Virus Vaccine

Neuzil, K. M. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00037-16 · Cited by 64 · see citing works

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein

Schepens, B., Sedeyn, K., Ginste, L. V., Baets, S. D., Schotsaert, M., Roose, K., Houspie, L., Ranst, M. A. V., Gilbert, B. E., van Rooijen, N., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404005 · Cited by 57 · see citing works

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

Olson, M. R., & Varga, S. M. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.8.1239 · Cited by 56 · see citing works

Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique

Roca, A., Abacassamo, F., Loscertales, M., Quintó, L., Gómez-Olivé, F. X., Fenwick, F., Sáiz, J., Toms, G. L., & Alonso, P. L. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10148 · Cited by 56 · see citing works

Correlates of vaccine protection from influenza and its complications

McCullers, J. A., & Huber, V. C. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18214 · Cited by 55 · see citing works

Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease

Jorquera, P. A., Choi, Y., Oakley, K. E., Powell, T., Boyd, J. G., Palath, N., Haynes, L. M., Anderson, L. J., & Tripp, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074905 · Cited by 54 · see citing works

Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

Mousa, J. J., Sauer, M. F., Sevy, A. M., Finn, J. A., Bates, J. T., Alvarado, G. S., King, H. G., Loerinc, L. B., Fong, R. H., Doranz, B. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609449113 · Cited by 53 · see citing works

Efficacy and Optimization of Palivizumab Injection Regimens Against Respiratory Syncytial Virus Infection

Gutfraind, A., Galvani, A. P., & Ancel, L. W. (2015) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2014.3804 · Cited by 49 · see citing works

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

Mejías, A., & Ramilo (2008) · Biologics · doi:10.2147/btt.s3104 · Cited by 48 · see citing works

Binding of estrogen receptors to switch sites and regulatory elements in the immunoglobulin heavy chain locus of activated B cells suggests a direct influence of estrogen on antibody expression

Jones, B. G., Penkert, R. R., Xu, B., Fan, Y., Neale, G. A. M., Gearhart, P. J., & Hurwitz, J. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.07.015 · Cited by 46 · see citing works

The Immune Response to Respiratory Syncytial Virus Infection: Friend or Foe?

Welliver, R. C. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8033-2 · Cited by 46 · see citing works

Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination

Biselli, R., Fattorossi, A., Matricardi, P. M., Nisini, R., Stroffolini, T., & D’Amelio, R. (1993) · Vaccine · doi:10.1016/0264-410x(93)90236-q · Cited by 42 · see citing works

Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels

Vissers, M., Ahout, I. M. L., de Jonge, M. I., & Ferwerda, G. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00590-15 · Cited by 40 · see citing works

Further characterization of an antigenic site of HIV-I gp120 recognized by virus neutralizing human monoclonal anti bodies

Schutten, M., McKnight, Á., Huisman, R. C., Thali, M., McKeating, J. A., Sodroski, J., Goudsmit, J., & Osterhaus, A. D. M. E. (1993) · AIDS · doi:10.1097/00002030-199307000-00003 · Cited by 35 · see citing works

Increasing Complexity of Vaccine Development

Plotkin, S. A. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu568 · Cited by 31 · see citing works

Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis

Via, W. V. L., Notario, G. F., Yu, X., Sharma, S., Noertersheuser, P. A., & Robbie, G. J. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.03.007 · Cited by 30 · see citing works

What Has 30 Years of HIV Vaccine Research Taught Us?

Esparza, J. (2013) · Vaccines · doi:10.3390/vaccines1040513 · Cited by 29 · see citing works

The antibody repertoire in evolution: Chance, selection, and continuity

Marchalonis, J. J., Adelman, M. K., Schluter, S. F., & Ramsland, P. A. (2005) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2005.06.011 · Cited by 29 · see citing works

Hotspots for Vitamin–Steroid–Thyroid Hormone Response Elements Within Switch Regions of Immunoglobulin Heavy Chain Loci Predict a Direct Influence of Vitamins and Hormones on B Cell Class Switch Recombination

Hurwitz, J. L., Penkert, R. R., Xu, B., Fan, Y., Partridge, J. F., Maul, R. W., & Gearhart, P. J. (2016) · Viral Immunology · doi:10.1089/vim.2015.0104 · Cited by 27 · see citing works

Pulmonary Eosinophilia Is Attenuated by Early Responding CD8 + Memory T Cells in a Murine Model of RSV Vaccine-Enhanced Disease

Stevens, W. W., Sun, J., Castillo, J., & Braciale, T. J. (2009) · Viral Immunology · doi:10.1089/vim.2009.0016 · Cited by 27 · see citing works

A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard

Hosken, N. A., Plikaytis, B. D., Trujillo, C., Mahmood, K., & Higgins, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.053 · Cited by 27 · see citing works

Respiratory Syncytial Virus (RSV): Neutralizing Antibody, a Correlate of Immune Protection

Piedra, P. A., Hause, A. M., & Aideyan, L. O. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3687-8_7 · Cited by 25 · see citing works

Systemic Immunoprophylaxis of Nasal Respiratory Syncytial Virus Infection in Cotton Rats

Sami, I. R., Piazza, F. M., Johnson, S. A., Darnell, M. E. R., Ottolini, M. G., Hemming, V. G., & Prince, G. A. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.2.440 · Cited by 25 · see citing works

Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease

Jorquera, P. A., Oakley, K. E., Powell, T., Palath, N., Boyd, J., & Tripp, R. A. (2015) · Vaccines · doi:10.3390/vaccines3040829 · Cited by 23 · see citing works

Heritability of vaccine-induced measles neutralizing antibody titers

Schaid, D. J., Haralambieva, I. H., Larrabee, B. R., Ovsyannikova, I. G., Kennedy, R. B., & Poland, G. A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.01.078 · Cited by 21 · see citing works

Role of MicroRNA in the Lung's Innate Immune Response

Cohen, T. S. (2016) · Journal of Innate Immunity · doi:10.1159/000452669 · Cited by 16 · see citing works

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen

Claydon, J., Sur, A., Callejas, A. M., Ladd, M., Kwan, E., Taylor, R. S., Turvey, S. E., Solimano, A. J., Lavoie, P. M., & Marr, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176152 · Cited by 16 · see citing works

Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines

Klasse, P. J., & Moore, J. P. (2012) · Retrovirology · doi:10.1186/1742-4690-9-80 · Cited by 15 · see citing works

Poliovirus Vaccine and Vaccine-Derived Polioviruses

Shulman, L. M., Manor, Y., & Sofer, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1009551 · Cited by 14 · see citing works

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)

(2002) · doi:10.1002/1521-4141(200208)32:8

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729 · see citing works

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine

Pellini, R., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Campo, F., Conti, L., VIRGILIO, A. D., Marco, F. D., Domenico, E. G. D., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100928 · Cited by 232 · see citing works

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants

Simões, E. A. F., Forleo‐Neto, E., Geba, G. P., Kamal, M. A., Yang, F., CICIRELLO, H. G., Houghton, M. R., Rideman, R., Zhao, Q., Benvin, S. L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa951 · Cited by 169 · see citing works

Updates on immunologic correlates of vaccine-induced protection

Plotkin, S. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2019.10.046 · Cited by 165 · see citing works

Immunopathology of RSV: An Updated Review

Bergeron, H. C., & Tripp, R. A. (2021) · Viruses · doi:10.3390/v13122478 · Cited by 109 · see citing works

RSV disease in infants and young children: Can we see a brighter future?

Baraldi, E., Lisi, G. C., Costantino, C., Heinrichs, J. H., Manzoni, P., Riccò, M., Roberts, M., & Vassilouthis, N. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2079322 · Cited by 99 · see citing works

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

Scheid, J. F., Barnes, C. O., Eraslan, B., Hudak, A., Keeffe, J. R., Cosimi, L. A., Brown, E., Muecksch, F., Weisblum, Y., Zhang, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.032 · Cited by 90 · see citing works

Recent updates on correlates of vaccine-induced protection

Plotkin, S. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081107 · Cited by 89 · see citing works

Decline of RSV-specific antibodies during the COVID-19 pandemic

den Hartog, G., van Kasteren, P. B., Schepp, R. M., Teirlinck, A. C., van der Klis, F. R. M., & van Binnendijk, R. S. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00763-0 · Cited by 75 · see citing works

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

Aliprantis, A. O., Wolford, D. G., Caro, L., Maas, B. M., Ma, H., Montgomery, D. L., Sterling, L. M., Hunt, A., Cox, K. S., Vora, K. A., et al. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.883 · Cited by 67 · see citing works

Antibody effector functions are associated with protection from respiratory syncytial virus

Bartsch, Y. C., Cizmeci, D., Kang, J., Zohar, T., Periasamy, S., Mehta, N., Tolboom, J. T. B. M., van der Fits, L., Sadoff, J., Comeaux, C. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.012 · Cited by 63 · see citing works

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Maas, B. M., Lommerse, J., Plock, N., Railkar, R. A., Cheung, S. Y. A., Caro, L., Chen, J., Liu, W., Zhang, Y., Huang, Q., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103651 · Cited by 58 · see citing works

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Noia, V. D., Pimpinelli, F., Renna, D., Barberi, V., Maccallini, M. T., Gariazzo, L., Pontone, M., Monti, A., Campo, F., Taraborelli, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2439 · Cited by 51 · see citing works

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

Brady, T. M., Cayatte, C., Roe, T. L., Speer, S. D., Ji, H., Machiesky, L., Zhang, T., Wilkins, D. E., Tuffy, K. M., & Kelly, E. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1283120 · Cited by 41 · see citing works

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers

Campo, F., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Conti, L., VIRGILIO, A. D., Marco, F. D., Noia, V. D., Domenico, E. G. D., et al. (2021) · Vaccines · doi:10.3390/vaccines9101125 · Cited by 40 · see citing works

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

Wilkins, D. E., Hamrén, U. W., Chang, Y., Clegg, L. E., Domachowske, J. B., Englund, J. A., Muller, W. J., Leach, A. J., Kelly, E. J., & Villafana, T. L. (2024) · PEDIATRICS · doi:10.1542/peds.2024-067174 · Cited by 37 · see citing works

Epitope-Specific Serological Assays for RSV: Conformation Matters

Phung, E., Chang, L. A., Morabito, K. M., Kanekiyo, M., Chen, M., Nair, D., Kumar, A., Chen, G. L., Ledgerwood, J. E., Graham, B. S., et al. (2019) · Vaccines · doi:10.3390/vaccines7010023 · Cited by 34 · see citing works

Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection

Patel, N., Massare, M., Tian, J.-H., Guebre‐Xabier, M., Lu, H., Zhou, H., Maynard, E. L., Scott, D. R., Ellingsworth, L. R., Glenn, G. M., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.07.089 · Cited by 34 · see citing works

Current state and challenges in respiratory syncytial virus drug discovery and development

Zou, G., Cao, S., Gao, Z., Yie, J., & Wu, J. Z. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105791 · Cited by 28 · see citing works

Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19

Kalkan-Yazıcı, M., Koç, M. M., Çetin, N. S., Karaaslan, E., Okay, G., Durdu, B., Sümbül, B., & Doymaz, M. Z. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000840 · Cited by 22 · see citing works

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies

Fleming, J. A., Baral, R., Higgins, D., Khan, S., Kochar, S., Li, Y., Ortiz, J. R., Cherian, T., Feikin, D. R., Jit, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2022.09.081 · Cited by 21 · see citing works

Respiratory syntycial virus: Current treatment strategies and vaccine approaches

Thornhill, E. M., Salpor, J., & Verhoeven, D. E. (2020) · Antiviral chemistry & chemotherapy · doi:10.1177/2040206620947303 · Cited by 20 · see citing works

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models

Saeland, E., van der Fits, L., Bolder, R., der Meer, M. H.-V., Drijver, J., van Polanen, Y., Vaneman, C., Tettero, L., Cox, F., Serroyen, J., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00637-7 · Cited by 18 · see citing works

Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials

Sinha, A., Railkar, R. A., Castagnini, L. A., Guerra, A., Likos, A., Lutkiewicz, J., Maas, B. M., Zang, X., Roadcap, B. A., Choi, Y., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107995 · Cited by 17 · see citing works

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization

Wilmschen, S., Schneider, S., Peters, F., Bayer, L., Issmail, L., Bánki, Z., Grünwald, T., von Laer, D., & Kimpel, J. (2019) · Vaccines · doi:10.3390/vaccines7030059 · Cited by 16 · see citing works

Will Attention by Vaccine Developers to the Host’s Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success?

Sealy, R. E., Jones, B. G., Surman, S. L., Penkert, R. R., Pelletier, S. W., Neale, G. A. M., & Hurwitz, J. L. (2019) · Vaccines · doi:10.3390/vaccines7010026 · Cited by 14 · see citing works

Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein

Xie, Q., Wang, Z., Ni, F., Chen, X., Ma, J., Patel, N., Lu, H., Liu, Y., Tian, J.-H., Flyer, D. C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210749 · Cited by 12 · see citing works

Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021–2023 RSV outbreaks to investigate the immunity debt hypothesis

Piliper, E. A., Reed, J. C., & Greninger, A. L. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02115-24 · Cited by 11 · see citing works

Longitudinal study of the immune response and memory following natural bovine respiratory syncytial virus infections in cattle of different age

Hägglund, S., Näslund, K., Svensson, A. C., Lefverman, C., Enül, H., Pascal, L., Siltenius, J., Holzhauer, M., Delabouglise, A., Österberg, J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274332 · Cited by 11 · see citing works

Strength and Durability of Respiratory Syncytial Virus Prefusion F Immunoglobulin G Following Infection and Exposure in a Household Cohort, 2014–2022

Rumfelt, K. E., Juntila-Raymond, C. L., Smith, M., Callear, A. P., Yang, Y., Monto, A. S., Lauring, A. S., & Martin, E. T. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf168 · Cited by 8 · see citing works

Self-amplifying mRNA vaccines protect elderly BALB/c mice against a lethal respiratory syncytial virus infection

Zuo, L., Liu, Q., Zhang, K., Zhao, L., Lin, S., Dai, Y., Sun, Y., Li, Y., Zhang, P., Shen, H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.013 · Cited by 7 · see citing works

Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients

Ye, X., Iwuchukwu, O. P., Avadhanula, V., Aideyan, L. O., McBride, T., Henke, D., Patel, K. D., Piedra, F.-A., Angelo, L. S., Shah, D. P., et al. (2021) · Viruses · doi:10.3390/v13060991 · Cited by 6 · see citing works

Correlates of risk of respiratory syncytial virus disease: a prospective cohort study

Frivold, C. J., Cox, S. N., Starita, L. M., Babu, T. M., Hoffman, K. L., Carone, M., Lockwood, C. M., Kuntz, J. L., Mularski, R. A., Varga, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63434-x · Cited by 5 · see citing works

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine

Bartsch, Y. C., Cizmeci, D., Yuan, D., Mehta, N., Tolboom, J. T. B. M., Paepe, E. D., van Heesbeen, R., SADOFF, J. C., Comeaux, C. A., Heijnen, E., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00771-23 · Cited by 5 · see citing works

Correlates of Protection

Plotkin, S. A., & Gilbert, P. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00004-9 · Cited by 4 · see citing works

Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study

Broad, J., Sparkes, D., Platt, N., Howells, A., Foulkes, S., Khawam, J., Cole, M. J., Andrews, N. J., Watson, C., Hopkins, S., et al. (2024) · NIHR Open Research · doi:10.3310/nihropenres.13517.1 · Cited by 3 · see citing works

Vaccine Design Informed by Virus-Induced Immunity

Penkert, R. R., Hankins, J. S., Young, N. S., & Hurwitz, J. L. (2020) · Viral Immunology · doi:10.1089/vim.2019.0138 · Cited by 3 · see citing works

Virus Reduction Neutralization Test and LI-COR Microneutralization Assay Bridging and WHO International Standard Calibration Studies for Respiratory Syncytial Virus

Sun, D., Homan, Y., Antonello, J. M., Giacone, D. G., Bogardus, L., Zhang, Y., Feng, W. M., Caro-Aguilar, I., Hsu, A. H.-M., Dellatore, S. M., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0097 · Cited by 2 · see citing works

Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study

Broad, J., Sparkes, D., Platt, N., Howells, A., Foulkes, S., Khawam, J., Cole, M. J., Andrews, N. J., Watson, C., Hopkins, S., et al. (2024) · NIHR Open Research · doi:10.3310/nihropenres.13517.2 · Cited by 2 · see citing works

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model‐Based Meta‐Analysis

Kashihara, Y., Li, Q., Shimizu, S., Diderichsen, P. M., Kotsuma, M., & Yoshihara, K. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70133 · Cited by 2 · see citing works

Journal of Preventive Medicine and Hygiene, Vol. 65 No. 2S1 (2024): Health Technology Assessment del vaccino ricombinante adiuvato contro il virus respiratorio sinciziale (Arexvy®)

Hygiene, J. O. P. M. A. (2024) · PubMed Central · doi:10.15167/2421-4248/jpmh2024.65.2s1 · Cited by 1 · see citing works

State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens

Ridelfi, M., Pierleoni, G., Fonseca, V. Z. G., Batani, G., Rappuoli, R., & Sala, C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2500-1878 · Cited by 1 · see citing works

Corrected and republished from: “Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021–2023 RSV outbreaks to investigate the immunity debt hypothesis”

Piliper, E. A., Reed, J. C., & Greninger, A. L. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01739-25 · Cited by 1 · see citing works

Vaccination Against Respiratory Syncytial Virus

Ruckwardt, T. J., Crank, M. C., Morabito, K. M., & Graham, B. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811924-2.00038-9 · Cited by 1 · see citing works

Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study

Broad, J., Sparkes, D., Platt, N., Howells, A., Foulkes, S., Khawam, J., Cole, M. J., Andrews, N. J., Watson, C., Hopkins, S., et al. (2024) · NIHR Open Research · doi:10.3310/nihropenres.13517.3 · Cited by 1 · see citing works

Approaching the End of the Era of Uncontrolled Respiratory Syncytial Virus Disease

Meissner, H. C. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa755 · Cited by 1 · see citing works

Data from Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Noia, V. D., Pimpinelli, F., Renna, D., Barberi, V., Maccallini, M. T., Gariazzo, L., Pontone, M., Monti, A., Campo, F., Taraborelli, E., et al. (2023) · doi:10.1158/1078-0432.c.6530936

Data from Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Noia, V. D., Pimpinelli, F., Renna, D., Barberi, V., Maccallini, M. T., Gariazzo, L., Pontone, M., Monti, A., Campo, F., Taraborelli, E., et al. (2023) · doi:10.1158/1078-0432.c.6530936.v1

Peer Review Report For: Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study [version 1; peer review: 1 approved with reservations]

(2024) · NIHR Open Research · doi:10.3310/nihropenres.14670.r31939

Clinical validation of an RSV neutralization assay and testing of cross-sectional sera pre- and post- RSV outbreaks from 2021-2023Preprint

Piliper, E. A., Reed, J. C., & Greninger, A. L. (2024) · medRxiv · doi:10.1101/2024.06.13.24308891

Peer Review Report For: Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study [version 2; peer review: 1 approved, 1 approved with reservations]

(2024) · NIHR Open Research · doi:10.3310/nihropenres.14822.r32503

Peer Review Report For: Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a pragmatic sub-study [version 3; peer review: 1 approved, 2 approved with reservations]

(2024) · NIHR Open Research · doi:10.3310/nihropenres.14978.r33758

A History of Respiratory Syncytial Viral Vaccine Development… What is next?

Salpor, J. (2018) · doi:10.31274/cc-20240624-43

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model‐Based Meta‐Analysis

Kashihara, Y., Li, Q., Shimizu, S., Diderichsen, P. M., Kotsuma, M., & Yoshihara, K. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70133 · Cited by 2 · see citing works

Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy

Abu-Raya, B., Reicherz, F., & Lavoie, P. M. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08948-8 · Cited by 18 · see citing works

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

Graham, B. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00972.x · Cited by 239 · see citing works

The journey to a respiratory syncytial virus vaccine

Mejías, A., Fernández, R. R., Oliva, S., Peeples, M. E., & Ramilo, O. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.03.017 · Cited by 140 · see citing works